【摘要】 目的：探究影响慢性心力衰竭患者经托伐普坦治疗效果的相关因素。方法：选取2021年1-11月抚州市第二人民医院接受托伐普坦治疗的60例慢性心力衰竭患者，评估所有患者治疗1个月后的效果，并分为无效组与有效组，收集并分析患者的临床资料，比较两组患者的相关资料的差异，并采用logistic回归分析方法探讨影响慢性心力衰竭患者托伐普坦治疗效果的独立危险因素。结果：单因素分析结果显示，有效组和无效组患者的年龄、性别、原发病、合并高血压、血钾水平比较，差异均无统计学意义（P>0.05）。有效组和无效组患者的体重指数（BMI）、心功能分级、合并糖尿病、血肌酐、血钠、白细胞介素-6(IL-6)、血清B型利钠肽（BNP）、N末端B型利钠肽原（NT-proBNP）水平比较，差异均有统计学意义（P<0.05）。多因素logistic回归分析中，高心功能分级、血肌酐、IL-6、BNP、NTproBNP均为影响慢性心力衰竭患者托伐普坦治疗效果的独立危险因素（P<0.05），高血纳水平为影响慢性心力衰竭患者托伐普坦治疗效果的保护因素（P<0.05）。结论：高心功能分级、血肌酐、IL-6、BNP、NT-proBNP均为影响慢性心力衰竭患者托伐普坦治疗效果的独立危险因素，高血钠水平为保护性因素，患者在接受临床治疗时应根据相应情况做出对应措施。更多还原

【Abstract】 Objective: To explore the related factors affecting the treatment effect of Tolvaptan in patients with chronic heart failure. Method: A total of 60 patients with chronic heart failure who received Tolvaptan in the Fuzhou Second People’s Hospital from January to November 2021 were selected to evaluate the treatment effect of all patients after 1 month of treatment, and they were divided into invalid group and effective group. The clinical data of the patients were collected and analyzed to compare the differences between the two groups. logistic regression analysis was used to investigate the independent risk factors influencing the therapeutic effect of Tolvaptan in patients with chronic heart failure. Result: Univariate analysis showed that there were no significant difference in age, gender, primary disease, combined hypertension and serum potassium level between the effective group and the ineffective group(P>0.05). There were statistically significant differences in body mass index(BMI), cardiac function grade, diabetes mellitus, serum creatinine, serum sodium, interleukin-6(IL-6), serum B-type natriuretic peptide(BNP) and N-terminal B-type natriuretic peptide(NT-proBNP) levels between effective group and ineffective group(P<0.05). In multivariate logistic regression analysis, high heart function grade, serum creatinine, IL-6, BNP and NTproBNP were all independent risk factors affecting the treatment effect of Tolvaptan in patients with chronic heart failure(P<0.05), high blood sodium level was a protective factor affecting the treatment effect of Tolvaptan in patients with chronic heart failure(P<0.05). Conclusion: High heart function grade, serum creatinine, IL-6, BNP, NT-proBNP are independent risk factors affecting the treatment effect of Tolvaptan in patients with chronic heart failure, high blood sodium level is protective factor, patients should make corresponding measures according to the corresponding situation when receiving clinical treatment.更多还原